DWC202407 1

Phase 1Small molecule

Daewoong Pharmaceutical Co. LTD.

DWC202407 1 is one of 8 small molecule programs targeting Drug Interactions. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Drug InteractionsNot yet recruiting

Drug InteractionsPhase 1

Not yet recruiting

Competition

Competitive Landscape

10 competitors in Drug Interactions

#DrugCompanyPhaseTrials

Ofev

Boehringer Ingelheim

Phase 1

4 2

Esbriet

LLegacy Health System

Phase 1

4 3

DWP16001

Daewoong Pharmaceutical Co. LTD.

Phase 1

1 4

Onglyza

AstraZeneca

Preclinical

1 5

Drug Cocktail

Eli Lilly

Phase 1

1 6

HRS-9813

Guangdong Hengrui Pharmaceutical Co., Ltd

Phase 1

1 7

DWC202407 1

Daewoong Pharmaceutical Co. LTD.

Phase 1

1 8

Taladegib

EEndeavor Biomedicines, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Drug Interactions1 trial

Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults

Not yet recruiting· Daewoong Pharmaceutical Co. LTD. logo

Daewoong Pharmaceutical Co. LTD.·Phase 1·NCT06644404·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DWC202407 1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DWC202407 1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DWC202407 1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Daewoong Pharmaceutical Co. LTD. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Daewoong Pharmaceutical Co. LTD.

DWC202407 1

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Drug Interactions1 trial

References

Drug Info

Quick Facts

Related News